Current and historical daily PE Ratio for ZYME (
Zymeworks Inc
) from 2017 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Zymeworks stock (ZYME) PE ratio as of Apr 23 2024 is 0.
More Details
Zymeworks Inc (ZYME) PE Ratio (TTM) Chart
Zymeworks Inc (ZYME) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1213
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Zymeworks PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
| 2024-03-08 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2023-12-29 | At Loss |
| 2024-03-05 | At Loss | 2023-12-28 | At Loss |
| 2024-03-04 | At Loss | 2023-12-27 | 3.5 |
| 2024-03-01 | At Loss | 2023-12-26 | 3.4 |
| 2024-02-29 | At Loss | 2023-12-22 | 3.2 |
| 2024-02-28 | At Loss | 2023-12-21 | 3.0 |
| 2024-02-27 | At Loss | 2023-12-20 | 3.0 |
| 2024-02-26 | At Loss | 2023-12-19 | 3.0 |
| 2024-02-23 | At Loss | 2023-12-18 | 2.9 |
| 2024-02-22 | At Loss | 2023-12-15 | 2.9 |
| 2024-02-21 | At Loss | 2023-12-14 | 2.9 |
| 2024-02-20 | At Loss | 2023-12-13 | 3.0 |
Zymeworks Inc (ZYME) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Zymeworks Inc
NAICS : 325412
SIC : 2836
ISIN : CA98985W1023
Share Class Description:
ZYME: Registered ShsDescription
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers